WuXi partners to boost biomarkers

By Nick Taylor

- Last updated on GMT

Related tags Qiagen Compound annual growth rate Clinical trial

WuXi AppTec is partnering with Qiagen to develop biomarkers, assay panels and personalised healthcare diagnostics and will use these, and existing technologies, to further clients’ projects.

Biomarker use has risen as companies seek to reduce the attrition rate, cutting overall development times and costs, by selecting the most promising candidates at the preclinical stage.

This has driven contract research organisations (CRO) to bolster their biomarker capabilities, with Covance, Quintiles and Icon all expanding their operations in the past six months.

WuXi is now strengthening its position through the deal with Qiagen. The partnership will be based at WuXi’s campus is Shanghai, China, with Qiagen providing the necessary instrumentation, training and consumables.

Victor Shi, Qiagen’s Asia-Pacific president, believes this may be the first laboratory of its kind in Asia to be equipped with a standardised, fully integrated, automated sample and assay technology platform.

WuXi will use this laboratory on sponsors’ drug discovery and development programmes, as well as molecular diagnostics in personalised healthcare.

Furthermore, the companies will collaborate on the development of biomarkers, assay panels, personalised healthcare diagnostics and other products that Qiagen is planning to bring to market.

WuXi and Qiagen will also co-promote each other’s services to their clients and are looking for further opportunities to expand and strengthen their relationship.

Biomarker market to be worth $20.5bn by 2014

In a 2009 report Markets and Markets​ predicted that the global biomarker market, covering tools and services, will be worth $20.5bn (€14.1bn) by 2014, achieving a compound annual growth rate (CAGR) of 19.7 per cent from 2009 to 2014.

More specifically, the biomarker services market will have a CAGR of 22.2 per cent over the period, driven primarily by increased use in clinical services.

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more